Topical Anti-Inflammatory Agents for Non-Infectious Uveitis: Current Treatment and Perspectives

References

• Williams GS, Westcott M. Practical Uveitis: Understanding the Grape. CRC Press; 2017.
   Google Scholar
• Mackenzie W. A Practical Treatise on the Diseases of the Eye. Forgotten Books; 1855.
   Google Scholar
• Forrester JV. New concepts on the role of autoimmunity in the pathogenesis of uveitis. Eye. 1992;6(5):433–446. doi:10.1038/eye.1992.93
   PubMed Web of Science ®Google Scholar
• Bloch-Michel E. International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol. 1987;103:234–235. doi:10.1016/S0002-9394(14)74235-7
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509–516.
   PubMed Web of Science ®Google Scholar
• Hogan MJ, Kimura SJ, Thygeson P. Signs and symptoms of uveitis: i. Anterior uveitis. Am J Ophthalmol. 1959;47(5):155–170. doi:10.1016/S0002-9394(14)78239-X
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. 1985;92(4):467–471. doi:10.1016/S0161-6420(85)34001-0
   PubMed Web of Science ®Google Scholar
• Deschenes J, Murray PI, Rao NA, Nussenblatt RB. International uveitis study group (IUSG) clinical classification of uveitis. Ocul Immunol Inflamm. 2008;16(1–2):1–2. doi:10.1080/09273940801899822
   PubMed Web of Science ®Google Scholar
• Miserocchi E, Fogliato G, Modorati G, Bandello F. Review on the worldwide epidemiology of uveitis. Eur J Ophthalmol. 2013;23(5):705–717. doi:10.5301/ejo.5000278
   PubMed Web of Science ®Google Scholar
• Durrani OM, Tehrani NN, Marr JE, Moradi P, Stavrou P, Murray PI. Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol. 2004;88(9):1159–1162. doi:10.1136/bjo.2003.037226
   PubMed Web of Science ®Google Scholar
• Thorne JE, Suhler E, Skup M, et al. Prevalence of noninfectious uveitis in the United States: a claims-based analysis. JAMA Ophthalmol. 2016;134(11):1237–1245. doi:10.1001/jamaophthalmol.2016.3229
   PubMed Web of Science ®Google Scholar
• Hsu YR, Huang JCC, Tao Y, et al. Noninfectious uveitis in the Asia–Pacific region. Eye. 2019;33(1):66–77. doi:10.1038/s41433-018-0223-z
   PubMed Web of Science ®Google Scholar
• García-Aparicio Á, García de Yébenes MJ, Otón T, Muñoz-Fernández S. Prevalence and incidence of uveitis: a systematic review and meta-analysis. Ophthalmic Epidemiol. 2021;28(6):461–468. doi:10.1080/09286586.2021.1882506
   PubMed Web of Science ®Google Scholar
• Rosenbaum JT, Bodaghi B, Couto C, et al. New observations and emerging ideas in diagnosis and management of non-infectious uveitis: a review. Semin Arthritis Rheum. 2019;49(3):438–445. doi:10.1016/j.semarthrit.2019.06.004
   PubMed Web of Science ®Google Scholar
• Tsirouki T, Dastiridou A, Symeonidis C, et al. A focus on the epidemiology of uveitis. Ocul Immunol Inflamm. 2018;26(1):2–16. doi:10.1080/09273948.2016.1196713
   PubMed Web of Science ®Google Scholar
• Nalcacioglu-Yuksekkaya P, Ozdal PC, Yazici A, Tirhis H. Clinical and demographic characteristics of patients with uveitis starting later in life. Ocul Immunol Inflamm. 2015;23(4):304–310. doi:10.3109/09273948.2014.938761
   PubMed Web of Science ®Google Scholar
• Tallouzi MO, Moore DJ, Bucknall N, et al. Outcomes important to patients with non-infectious posterior segment-involving uveitis: a qualitative study. BMJ Open Ophthalmol. 2020;5(1):e000481. doi:10.1136/bmjophth-2020-000481
   PubMed Web of Science ®Google Scholar
• Barry RJ, Nguyen QD, Lee RW, Murray PI, Denniston AK. Pharmacotherapy for uveitis: current management and emerging therapy. Clin Ophthalmol Auckl NZ. 2014;22(8):1891–1911.
   Google Scholar
• Barry RJ, Sutcliffe N, Isenberg DA, et al. The Sjögren’s Syndrome Damage Index--a damage index for use in clinical trials and observational studies in primary Sjögren’s syndrome. Rheumatol Oxf Engl. 2008;47(8):1193–1198. doi:10.1093/rheumatology/ken164
   PubMed Web of Science ®Google Scholar
• Skopouli FN, Dafni U, Ioannidis JP, Moutsopoulos HM. Clinical evolution, and morbidity and mortality of primary Sjögren’s syndrome. Semin Arthritis Rheum. 2000;29(5):296–304. doi:10.1016/S0049-0172(00)80016-5
   PubMed Web of Science ®Google Scholar
• Jones J, Francis P. Ophthalmic utility of topical bromfenac, a twice-daily nonsteroidal anti-inflammatory agent. Expert Opin Pharmacother. 2009;10(14):2379–2385. doi:10.1517/14656560903188425
   PubMed Web of Science ®Google Scholar
• Woods AC. Clinical and experimental observation on the use of ACTH and cortisone in ocular inflammatory disease. Am J Ophthalmol. 1950;33(9):1325–1351. doi:10.1016/0002-9394(50)91827-7
   PubMed Web of Science ®Google Scholar
• Watson D, Noble MJ, Dutton GN, Midgley JM, Healey TM. Penetration of topically applied dexamethasone alcohol into human aqueous humor. Arch Ophthalmol. 1988;106(5):686–687. doi:10.1001/archopht.1988.01060130748037
   PubMedGoogle Scholar
• Watson DG, McGhee CNJ, Midgley JM, Dutton GN, Noble MJ. Penetration of topically applied betamethasone sodium phosphate into human aqueous humour. Eye. 1990;4(4):603–606. doi:10.1038/eye.1990.84
   PubMed Web of Science ®Google Scholar
• McGhee CNJ, Noble MJ, Watson DG, et al. Penetration of topically applied prednisolone sodium phosphate into human aqueous humour. Eye. 1989;3(4):463–467. doi:10.1038/eye.1989.69
   PubMed Web of Science ®Google Scholar
• Sulaiman RS, Kadmiel M, Cidlowski JA. Glucocorticoid receptor signaling in the eye. Steroids. 2018;133:60–66. doi:10.1016/j.steroids.2017.11.002
   PubMed Web of Science ®Google Scholar
• Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. N Engl J Med. 2005;353(16):1711–1723. doi:10.1056/NEJMra050541
   PubMed Web of Science ®Google Scholar
• Saklatvala J, Nagase H, Salvesen G, Dean J, Clark A. Control of the expression of inflammatory response genes. In: Biochemical Society Symposia. Portland Press; 2003:95–106.
   Google Scholar
• Gille J, Reisinger K, Westphal-Varghese B, Kaufmann R. Decreased mRNA stability as a mechanism of glucocorticoid-mediated inhibition of vascular endothelial growth factor gene expression by cultured keratinocytes. J Invest Dermatol. 2001;117(6):1581–1587. doi:10.1046/j.0022-202x.2001.01573.x
   PubMed Web of Science ®Google Scholar
• Hafezi-Moghadam A, Simoncini T, Yang Z, et al. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med. 2002;8(5):473–479. doi:10.1038/nm0502-473
   PubMed Web of Science ®Google Scholar
• Airody A, Heath G, Lightman S, Gale R. Non-infectious uveitis: optimising the therapeutic response. Drugs. 2016;76(1):27–39. doi:10.1007/s40265-015-0502-y
   PubMed Web of Science ®Google Scholar
• Phulke S, Kaushik S, Kaur S, Pandav SS. Steroid-induced glaucoma: an avoidable irreversible blindness. J Curr Glaucoma Pract. 2017;11(2):67. doi:10.5005/jp-journals-10028-1226
   PubMedGoogle Scholar
• Raizman M. Corticosteroid therapy of eye disease: fifty years later. Arch Ophthalmol. 1996;114(8):1000–1001. doi:10.1001/archopht.1996.01100140208016
   PubMedGoogle Scholar
• Pleyer U, Ursell PG, Rama P. Intraocular pressure effects of common topical steroids for post-cataract inflammation: are they all the same? Ophthalmol Ther. 2013;2(2):55–72. doi:10.1007/s40123-013-0020-5
   PubMedGoogle Scholar
• Daniel E, Pistilli M, Kothari S, et al. Risk of ocular hypertension in adults with noninfectious uveitis. Ophthalmology. 2017;124(8):1196–1208. doi:10.1016/j.ophtha.2017.03.041
   PubMed Web of Science ®Google Scholar
• Din NM, Isa H, Taylor SR, Barton K, Lightman SL. Intraocular pressure elevation in uveitis. Expert Rev Ophthalmol. 2012;7(1):45–59. doi:10.1586/eop.11.75
   Google Scholar
• Cantrill HL, Palmberg PF, Zink HA, Waltman SR, Podos SM, Becker B. Comparison of in vitro potency of corticosteroids with ability to raise intraocular pressure. Am J Ophthalmol. 1975;79(6):1012–1017. doi:10.1016/0002-9394(75)90687-X
   PubMed Web of Science ®Google Scholar
• Loteprednol Etabonate US Uveitis Study Group. Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Am J Ophthalmol. 1999;127(5):537–544. doi:10.1016/S0002-9394(99)00034-3
   PubMed Web of Science ®Google Scholar
• Sallam A, Sheth HG, Habot-Wilner Z, Lightman S. Outcome of raised intraocular pressure in uveitic eyes with and without a corticosteroid-induced hypertensive response. Am J Ophthalmol. 2009;148(2):207–213.e1. doi:10.1016/j.ajo.2009.02.032
   PubMed Web of Science ®Google Scholar
• Basilious A, Lloyd JC. Posterior subcapsular cataracts and hypotony secondary to severe pembrolizumab induced uveitis: case report. Can J Ophthalmol J Can Ophtalmol. 2016;51(1):e4–e6. doi:10.1016/j.jcjo.2015.09.008
   PubMed Web of Science ®Google Scholar
• Dikshit SK, Avasthi PN. Posterior lenticular opacities in children on corticosteroid therapy. Indian J Pediatr. 1965;32(3):93–96. doi:10.1007/BF02756568
   PubMedGoogle Scholar
• Jobling AI, Augusteyn RC. What causes steroid cataracts? A review of steroid-induced posterior subcapsular cataracts. Clin Exp Optom. 2002;85(2):61–75. doi:10.1111/j.1444-0938.2002.tb03011.x
   PubMedGoogle Scholar
• Dick AD, Tundia N, Sorg R, et al. Risk of ocular complications in patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis. Ophthalmology. 2016;123(3):655–662. doi:10.1016/j.ophtha.2015.10.028
   PubMed Web of Science ®Google Scholar
• Blum-Hareuveni T, Seguin-Greenstein S, Kramer M, et al. Risk factors for the development of cataract in children with uveitis. Am J Ophthalmol. 2017;177:139–143. doi:10.1016/j.ajo.2017.02.023
   PubMed Web of Science ®Google Scholar
• Thorne JE, Woreta FA, Dunn JP, Jabs DA. Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. Ophthalmology. 2010;117(7):1436–1441. doi:10.1016/j.ophtha.2009.12.003
   PubMed Web of Science ®Google Scholar
• Schallhorn JM, Niemeyer KM, Browne EN, Chhetri P, Acharya NR. Difluprednate for the treatment of uveitic cystoid macular edema. Am J Ophthalmol. 2018;191:14–22. doi:10.1016/j.ajo.2018.03.027
   PubMed Web of Science ®Google Scholar
• Petrushkin H, Rogers D, Pavesio C. The use of topical non-steroidal anti-inflammatory drugs for uveitic cystoid macular edema. Ocul Immunol Inflamm. 2018;26(5):795–797. doi:10.1080/09273948.2016.1269931
   PubMed Web of Science ®Google Scholar
• Sheppard JD. Topical bromfenac for prevention and treatment of cystoid macular edema following cataract surgery: a review. Clin Ophthalmol Auckl NZ. 2016;10:2099. doi:10.2147/OPTH.S86971
   PubMed Web of Science ®Google Scholar
• Ahuja M, Dhake AS, Sharma SK, Majumdar DK. Topical ocular delivery of NSAIDs. AAPS J. 2008;10(2):229–241. doi:10.1208/s12248-008-9024-9
   PubMed Web of Science ®Google Scholar
• Waterbury L, Kunysz EA, Beuerman R. Effects of steroidal and non-steroidal anti-inflammatory agents on corneal wound healing. J Ocul Pharmacol. 1987;3(1):43–54. doi:10.1089/jop.1987.3.43
   PubMedGoogle Scholar
• Radwan AE, Arcinue CA, Yang P, Artornsombudh P, Abu Al-Fadl EM, Foster CS. Bromfenac alone or with single intravitreal injection of bevacizumab or triamcinolone acetonide for treatment of uveitic macular edema. Graefes Arch Clin Exp Ophthalmol. 2013;251(7):1801–1806. doi:10.1007/s00417-013-2309-4
   PubMed Web of Science ®Google Scholar
• Al-Ani HH, Sims JL, Tomkins-Netzer O, Lightman S, Niederer RL. Vision loss in anterior uveitis. Br J Ophthalmol. 2020;104(12):1652–1657. doi:10.1136/bjophthalmol-2019-315551
   PubMed Web of Science ®Google Scholar
• Loh AR, Acharya NR. Incidence rates and risk factors for ocular complications and vision loss in HLA-B27-associated uveitis. Am J Ophthalmol. 2010;150(4):534–542. doi:10.1016/j.ajo.2010.04.031
   PubMed Web of Science ®Google Scholar
• Gregory AC, Kempen JH, Daniel E, et al. Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the SITE study. Ophthalmology. 2013;120(1):186–192. doi:10.1016/j.ophtha.2012.07.052
   PubMed Web of Science ®Google Scholar
• Rothova A, Suttorp-van Schulten MS, Treffers WF, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80(4):332–336. doi:10.1136/bjo.80.4.332
   PubMed Web of Science ®Google Scholar
• Eperjesi F, Jones K. Cycloplegic refraction in optometric practice. Optom Pract. 2005;6(3):107.
   Google Scholar
• Ihekaire DE. The comparative efficacy of Cycloplegic drugs–Tropicamide and Cyclopentolate on school children. Int J Sci Res Educ. 2012;5(3):223–246.
   Google Scholar
• Shah SM, Spalton DJ, Smith SE. Measurement of aqueous cells and flare in normal eyes. Br J Ophthalmol. 1991;75(6):348–352. doi:10.1136/bjo.75.6.348
   PubMed Web of Science ®Google Scholar
• Ikeji F, Pavesio C, Bunce C, White E. Quantitative assessment of the effects of pupillary dilation on aqueous flare in eyes with chronic anterior uveitis using laser flare photometry. Int Ophthalmol. 2010;30(5):491–494. doi:10.1007/s10792-010-9373-0
   PubMedGoogle Scholar
• Yilmaz M, Guven Yilmaz S, Palamar M, Ates H, Yagci A. The effects of tropicamide and cyclopentolate hydrochloride on laser flare meter measurements in uveitis patients: a comparative study. Int Ophthalmol. 2021;41(3):853–857. doi:10.1007/s10792-020-01639-3
   PubMed Web of Science ®Google Scholar
• Kalogeropoulos D, Sung VC. Pathogenesis of uveitic glaucoma. J Curr Glaucoma Pract. 2018;12(3):125. doi:10.5005/jp-journals-10078-1236
   PubMedGoogle Scholar
• Sng CC, Ang M, Barton K. Uveitis and glaucoma: new insights in the pathogenesis and treatment. Prog Brain Res. 2015;221:243–269.
   PubMed Web of Science ®Google Scholar
• Becker HI, Walton RC, Diamant JI, Zegans ME. Anterior uveitis and concurrent allergic conjunctivitis associated with long-term use of topical 0.2% brimonidine tartrate. Arch Ophthalmol. 2004;122(7):1063–1066. doi:10.1001/archopht.122.7.1063
   PubMedGoogle Scholar
• Byles DB, Frith P, Salmon JF. Anterior uveitis as a side effect of topical brimonidine. Am J Ophthalmol. 2000;130(3):287–291. doi:10.1016/S0002-9394(00)00491-8
   PubMed Web of Science ®Google Scholar
• Cates CA, Jeffrey MN. Granulomatous anterior uveitis associated with 0.2% topical brimonidine. Eye. 2003;17(5):670–671. doi:10.1038/sj.eye.6700392
   PubMed Web of Science ®Google Scholar
• Hopf S, Mercieca K, Pfeiffer N, Prokosch-Willing V. Brimonidine-associated uveitis–a descriptive case series. BMC Ophthalmol. 2020;20(1):1–7. doi:10.1186/s12886-020-01762-w
   PubMed Web of Science ®Google Scholar
• Bito LZ. Prostaglandins: a new approach to glaucoma management with a new, intriguing side effect. Surv Ophthalmol. 1997;41:S1–S14. doi:10.1016/S0039-6257(97)80002-1
   PubMed Web of Science ®Google Scholar
• Holló G. The side effects of the prostaglandin analogues. Expert Opin Drug Saf. 2007;6(1):45–52. doi:10.1517/14740338.6.1.45
   PubMed Web of Science ®Google Scholar
• Warwar RE, Bullock JD, Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use: experience and incidence in a retrospective review of 94 patients. Ophthalmology. 1998;105(2):263–268. doi:10.1016/S0161-6420(98)92977-3
   PubMed Web of Science ®Google Scholar
• Fechtner RD, Khouri AS, Zimmerman TJ, et al. Anterior uveitis associated with latanoprost. Am J Ophthalmol. 1998;126(1):37–41. doi:10.1016/S0002-9394(98)00071-3
   PubMed Web of Science ®Google Scholar
• Hu J, Vu JT, Hong B, Gottlieb C. Uveitis and cystoid macular oedema secondary to topical prostaglandin analogue use in ocular hypertension and open angle glaucoma. Br J Ophthalmol. 2020;104(8):1040–1044. doi:10.1136/bjophthalmol-2019-315280
   PubMed Web of Science ®Google Scholar
• Baudouin C, Labbé A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29(4):312–334. doi:10.1016/j.preteyeres.2010.03.001
   PubMed Web of Science ®Google Scholar
• Aguayo Bonniard A, Yeung JY, Chan CC, Birt CM. Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK). Expert Opin Drug Metab Toxicol. 2016;12(11):1279–1289. doi:10.1080/17425255.2016.1209481
   PubMed Web of Science ®Google Scholar
• Datta S, Baudouin C, Brignole-Baudouin F, Denoyer A, Cortopassi GA. The eye drop preservative benzalkonium chloride potently induces mitochondrial dysfunction and preferentially affects LHON mutant cells. Invest Ophthalmol Vis Sci. 2017;58(4):2406–2412. doi:10.1167/iovs.16-20903
   PubMed Web of Science ®Google Scholar
• Dart J. Corneal toxicity: the epithelium and stroma in iatrogenic and factitious disease. Eye. 2003;17(8):886–892. doi:10.1038/sj.eye.6700576
   PubMed Web of Science ®Google Scholar
• Korenfeld MS, Silverstein SM, Cooke DL, Vogel R, Crockett RS, Emulsion DO. Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain. J Cataract Refract Surg. 2009;35(1):26–34. doi:10.1016/j.jcrs.2008.09.024
   PubMed Web of Science ®Google Scholar
• Smith S, Lorenz D, Peace J, McLeod K, Crockett RS, Vogel R. Difluprednate ophthalmic emulsion 0.05%(Durezol®) administered two times daily for managing ocular inflammation and pain following cataract surgery. Clin Ophthalmol Auckl NZ. 2010;4:983. doi:10.2147/OPTH.S10696
   PubMedGoogle Scholar
• Slabaugh MA, Herlihy E, Ongchin S, Van Gelder RN. Efficacy and potential complications of difluprednate use for pediatric uveitis. Am J Ophthalmol. 2012;153(5):932–938. doi:10.1016/j.ajo.2011.10.008
   PubMed Web of Science ®Google Scholar
• Kakimoto H, Takamura Y, Arimura S, et al. Effect of 0.05% difluprednate ophthalmic emulsion on proinflammatory cytokine levels after retinal laser photocoagulation in rabbits. J Ocul Pharmacol Ther. 2018;34(5):410–415. doi:10.1089/jop.2017.0109
   PubMed Web of Science ®Google Scholar
• Kersey JP, Broadway DC. Corticosteroid-induced glaucoma: a review of the literature. Eye. 2006;20(4):407–416. doi:10.1038/sj.eye.6701895
   PubMed Web of Science ®Google Scholar
• Armaly MF. Effect of corticosteroids on intraocular pressure and fluid dynamics: i. The effect of dexamethasone* in the normal eye. Arch Ophthalmol. 1963;70(4):482–491. doi:10.1001/archopht.1963.00960050484010
   PubMedGoogle Scholar
• Kawamura M, Zako M. Long-term stability of uveitis with faint anterior chamber flare treated with once-daily topical ophthalmic betamethasone. Inflammation. 2014;37(2):417–425. doi:10.1007/s10753-013-9754-4
   PubMed Web of Science ®Google Scholar
• Fairbairn WD, Thorson JC. Fluorometholone: anti-inflammatory and intraocular pressure effects. Arch Ophthalmol. 1971;86(2):138–141. doi:10.1001/archopht.1971.01000010140004
   PubMedGoogle Scholar
• Shokoohi-Rad S, Daneshvar R, Jafarian-Shahri M, Rajaee P. Comparison between Betamethasone, Fluorometholone and Loteprednol Etabonate on intraocular pressure in patients after keratorefractive surgery. J Curr Ophthalmol. 2018;30(2):130–135. doi:10.1016/j.joco.2017.11.008
   PubMed Web of Science ®Google Scholar
• Stewart R, Horwitz B, Howes J, Novack GD, Hart K. Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5 for postoperative inflammation. J Cataract Refract Surg. 1998;24(11):1480–1489. doi:10.1016/S0886-3350(98)80170-3
   PubMed Web of Science ®Google Scholar
• Lane SS, Holland EJ. Loteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the treatment of inflammation after cataract surgery. J Cataract Refract Surg. 2013;39(2):168–173. doi:10.1016/j.jcrs.2012.10.039
   PubMed Web of Science ®Google Scholar
• Filippelli M, Gelso A, Rinaldi M, et al. Effects of topical low-dose preservative-free hydrocortisone on intraocular pressure in patients affected by ocular surface disease with and without glaucoma. Graefes Arch Clin Exp Ophthalmol. 2022;260(1):247–253. doi:10.1007/s00417-021-05345-3
   PubMed Web of Science ®Google Scholar
• Feiler DL, Srivastava SK, Pichi F, Bena J, Lowder CY. Resolution of noninfectious uveitic cystoid macular edema with topical difluprednate. Retina. 2017;37(5):844–850. doi:10.1097/IAE.0000000000001243
   PubMed Web of Science ®Google Scholar
• Symes RJ, Forooghian F. Topical difluprednate monotherapy for uveitic macular edema. Can J Ophthalmol. 2016;51(1):47–49. doi:10.1016/j.jcjo.2015.10.007
   PubMed Web of Science ®Google Scholar
• Onishi SM, Asahi MG, Chou C, Gallemore RP. Topical difluprednate for the treatment of Harada’s disease. Clin Ophthalmol Auckl NZ. 2015;9:157.
   PubMedGoogle Scholar
• Hariprasad SM, Callanan D. Topical nepafenac 0.1% for treatment of chronic uveitic cystoid macular edema. Retin Cases Brief Rep. 2008;2(4):304–308. doi:10.1097/ICB.0b013e31809ed9db
   PubMedGoogle Scholar
• Saade JS, Istambouli R, AbdulAal M, Antonios R, Hamam RN. Bromfenac 0.09% for the treatment of macular edema secondary to noninfectious uveitis. Middle East Afr J Ophthalmol. 2021;28(2):98. doi:10.4103/meajo.meajo_134_21
   PubMed Web of Science ®Google Scholar
• Gallenga PE, Mastropasqua L, Lobefolo L, et al. Efficacy of diclofenac eyedrops in preventing postoperative inflammation and long-term cystoid macular edema. J Cataract Refract Surg. 1997;23(8):1183–1189. doi:10.1016/S0886-3350(97)80313-6
   PubMed Web of Science ®Google Scholar
• Heier J, Cheetham JK, DeGryse R, et al. Ketorolac tromethamine 0.5% ophthalmic solution in the treatment of moderate to severe ocular inflammation after cataract surgery: a randomized, vehicle-controlled clinical trial. Am J Ophthalmol. 1999;127(3):253–259. doi:10.1016/S0002-9394(98)00413-9
   PubMed Web of Science ®Google Scholar
• Suzuki T, Hayakawa K, Nakagawa Y, Onouchi H, Ogata M, Kawai K. Topical dorzolamide for macular edema in the early phase after vitrectomy and epiretinal membrane removal. Clin Ophthalmol Auckl NZ. 2013;7:549. doi:10.2147/OPTH.S42188
   PubMedGoogle Scholar
• Grover S, Apushkin MA, Fishman GA. Topical dorzolamide for the treatment of cystoid macular edema in patients with retinitis pigmentosa. Am J Ophthalmol. 2006;141(5):850–858. doi:10.1016/j.ajo.2005.12.030
   PubMed Web of Science ®Google Scholar
• Mazet R, Yaméogo JBG, Wouessidjewe D, Choisnard L, Gèze A. Recent advances in the design of topical ophthalmic delivery systems in the treatment of ocular surface inflammation and their biopharmaceutical evaluation. Pharmaceutics. 2020;12(6). doi:10.3390/pharmaceutics12060570
   Web of Science ®Google Scholar
• Kim SJ, Flach AJ, Jampol LM. Nonsteroidal anti-inflammatory drugs in ophthalmology. Surv Ophthalmol. 2010;55(2):108–133. doi:10.1016/j.survophthal.2009.07.005
   PubMed Web of Science ®Google Scholar